News
- Author:
- Neil Osterweil
Publish date: December 8, 2017
SAN ANTONIO - Five years of additional therapy with anastrozole was no more effective than 2 additional years.
Video
- Author:
- Neil Osterweil
Publish date: December 8, 2017
SAN ANTONIO – Dr. Debu Tripathy discusses the therapeutic benefits and quality of life improvements aof adding ribociclib to endocr...
Video
- Author:
- Neil Osterweil
Publish date: December 8, 2017
SAN ANTONIO – Five years of additional therapy with anastrozole was no more effective than 2 additional years after 5 years of initial endocrine th...
News
- Author:
- Neil Osterweil
Publish date: December 8, 2017
SAN ANTONIO – Among nearly 4,500 women enrolled in the POETIC Trial, TTR and OS were similar whether patients received AI therapy or not.
News
- Author:
- Neil Osterweil
Publish date: December 7, 2017
SAN ANTONIO – The median PFS for women treated with ribociclib plus endocrine therapy was 23.8 months, vs. 13 months for women treated with the sam...
Video
- Author:
- Neil Osterweil
Publish date: December 7, 2017
SAN ANTONIO - Dr. Aditya Bardia discusses the 34% overall response rate and describes planned clinical trials pitting the ADC against standard...
News
- Author:
- Neil Osterweil
Publish date: December 4, 2017
Five key recommendations have been updated since the guidelines were first published in 2001.
News
- Author:
- Neil Osterweil
Publish date: December 4, 2017
Larynx-preserving techniques do not compromise survival in patients with early-stage laryngeal cancers.
News
- Author:
- Neil Osterweil
Publish date: November 30, 2017
NEW YORK – Should autologous stem cell transplantation or novel therapies be the next step when a patient with follicular lymphoma experiences earl...
News
- Author:
- Neil Osterweil
Publish date: November 28, 2017
Treatment successes in other hematologic malignancies offer promise for MZL.
News
- Author:
- Neil Osterweil
Publish date: November 27, 2017
A case of epidermotropic MZL in an otherwise healthy 69-year-old man shows the efficacy of rituximab.
News
- Author:
- Neil Osterweil
Publish date: November 27, 2017
The study assessed FND-R or CHOP-R as upfront chemotherapy regimens in patients with either extranodal, nodal, or splenic MZL.
News
- Author:
- Neil Osterweil
Publish date: November 22, 2017
New data from the ZUMA-1 and JULIET studies will be presented at ASH 2017.
News
- Author:
- Neil Osterweil
Publish date: November 18, 2017
There was no clear standard treatment approach for patients with CLL who discontinued ibrutinib or for whom ibrutinib did not work, in a multicente...
News
- Author:
- Neil Osterweil
Publish date: November 15, 2017
NEW YORK – Two leading multiple myeloma experts question whether it’s time to incorporate minimal residual disease measures into daily practice.
